Dr. Herman Jay Herman, M.D.

Contact Dr. Herman

111 S. 11th Street
Suite 8220, Gibbon Building
Philadelphia, PA 19107

(215) 955-8244
(215) 923-3836 fax

Research and Clinical Interests
Dr. Herman's research interests have been focused in the fields of platelet transfusion practice, pediatric transfusion, platelet and neutrophil immune disorders, blood stem cell collection and new apheresis technology. His clinical interests have focused on laboratory management, immunohematologic disorders and non-malignant hematologic diseases of children and adults, especially platelet disorders.

Publications

Most recent Peer-reviewed Publications

  1. Immunoglobulin therapy and thrombosis: Coincidence or causation?
  2. RhIG for the treatment of immune thrombocytopenia: Consensus and controversy (CME)
  3. Systematic criteria for type and screen based on procedure's probability of erythrocyte transfusion
  4. Platelet refractoriness in acquired hemophagocytic syndrome
  5. Transfection of human platelets with short interfering RNA
  6. Autoimmunity in transfusion babesiosis: A spectrum of clinical presentations
  7. In Reply
  8. Prevention of D sensitization after mismatched transfusion of blood components: Toward optimal use of RhIG
  9. Acute hypotensive transfusion reaction during liver transplantation in a patient on angiotensin converting enzyme inhibitors from low aminopeptidase P activity
  10. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation
  11. Lack of effect of donor-recipient ABO mismatching on outcome following allogeneic hematopoietic stem cell transplantation
  12. Acute hypertensive transfusion reactions
  13. Alternative explanation for "muddy plasma" [3]
  14. Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: Case report and review of the literature
  15. Apheresis platelet transfusions: Does ABO matter?
  16. Platelet dosing
  17. Single-donor platelets reduce the risk of septic platelet transfusion reactions.
  18. Early prediction of poor hematopoietic progenitor cell (HPC) mobilization
  19. Severe cutaneous ulceration following treatment with thalidomide for GVHD
  20. Economic consequences of alterations in platelet transfusion dose: Analysis of a prospective, randomized, double-blind trial

View All Publications